Neuromuscular Disease Therapeutics Market to Grow by USD 4.46 bn

Neuromuscular Disease Therapeutics Market: Driver The novel approvals is one of the key factors driving…

Neuromuscular Disease Therapeutics Market: Driver

The novel approvals is one of the key factors driving the growth of the neuromuscular disease therapeutics market. There has been an increase in drug approvals in the market for treating various neuromuscular indications in recent years. This is due to the advanced research being conducted on highly morbid and progressive indications. Spinal muscular atrophy is one of the major neuromuscular diseases for which the market has witnessed therapeutic approvals. Spinal muscular atrophy is morbid and rapidly progressive neuromuscular. It is caused by the death of a type of nerve cells, called motor neurons, in the spinal cord. Treatments using drugs are not effective and do not stop the disease progression due to the rapidly progressive nature of the disease. To overcome this challenge, various vendors are conducting research on the development of novel gene therapies and antisense therapies that can stop the progression of the disease and increase the life expectancy of patients.

Learn about more drivers impacting the growth of the market. Request Our Free Sample

Neuromuscular Disease Therapeutics Market: Some Key Vendors and their Offerings

  • AFM-Telethon – The company offers GNT 0004 that is based on an adeno-associated virus capsid and an optimized gene.
  • Biogen Inc. – The company offers SPINRAZA, which is a prescription medicine used to treat spinal muscular atrophy in pediatric and adult patients.
  • Brainstorm Cell Therapeutics Inc. – The company offers MSC-NTF cells that are safe and well-tolerated, with the majority of adverse events being mild or moderate in severity reduction in the rate of ALS disease progression.
  • F. Hoffmann-La Roche Ltd. – The company offers Evrysdi, which is used for the treatment of spinal muscular atrophy in adults and children two months of age and older.
  • Mitsubishi Chemical Holdings Corp. – The company offers efficacy and safety of FTY720 in patients with relapsing multiple sclerosis.

Get lifetime access to our Technavio Insights. Subscribe now to our most popular “Lite Plan” billed annually at USD 3000. View 3 reports monthly and Download 3 Reports Annually!

Neuromuscular Disease Therapeutics Market: Segmentation Analysis

By type, the neuromuscular disease therapeutics market has been segmented by biologics and small molecules. The biologics segment will have significant market share growth during the forecast period. SPINRAZA by Biogen and ZOLGENSMA by Novartis will dominate this segment.

By geography, the neuromuscular disease therapeutics market has been segmented by North America, Europe, Asia, and ROW. North America will have significant market share growth during the forecast period. The increasing prevalence of neuromuscular diseases and the availability of highly advanced therapeutics for the treatment of these diseases will facilitate the neuromuscular disease therapeutics market growth in North America over the forecast period.

Know more about the global trends impacting the future of the market, Download Free Sample Report

Related Reports:

Radiopharmaceuticals Market by Application and Geography – Forecast and Analysis 2022-2026

Central Nervous System (CNS) Stimulant Drugs Market by Application and Geography – Forecast and Analysis 2022-2026

Neuromuscular Disease Therapeutics Market Scope

Report Coverage

Details

Page number

120

Base year

2020

Forecast period

2021-2025

Growth momentum & CAGR

Accelerate at a CAGR of 9.64%

Market growth 2021-2025

USD 4.46 billion

Market structure

Fragmented

YoY growth (%)

8.48

Regional analysis

North America, Europe, Asia, and ROW

Performing market contribution

North America at 38%

Key consumer countries

US, Canada, Germany, UK, and China

Competitive landscape

Leading companies, Competitive strategies, Consumer engagement scope

Key companies profiled

AFM-Telethon, Biogen Inc., Brainstorm Cell Therapeutics Inc., F. Hoffmann-La Roche Ltd., Mitsubishi Chemical Holdings Corp., Novartis AG, Pfizer Inc., PTC Therapeutics Inc., Sanofi SA, and Sarepta Therapeutics Inc.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Table of Contents

1. Executive Summary                         

2. Market Landscape                            

               2.1 Market ecosystem             

                              2.1.1 Parent Market

                              Exhibit 01:  Parent market

                              Exhibit 02:  Market characteristics

               2.2 Value chain analysis           

                              Exhibit 03:  Value chain analysis: Pharmaceuticals

                              2.2.1 Research and development (R&D) and drug discovery

                              2.2.2 Integration and product development

                              2.2.3 Manufacturing

                              2.2.4 Outbound logistics

                              2.2.5 Marketing and sales

                              2.2.6 Support services

                              2.2.7 Industry innovations

3. Market Sizing                      

               3.1 Market definition

                              Exhibit 04:  Offerings of vendors included in the market definition

               3.2 Market segment analysis  

                              Exhibit 05:  Market segments

               3.3 Market size 2020 

               3.4 Market outlook: Forecast for 2020 – 2025 

                              3.4.1 Estimating growth rates for emerging and high-growth markets

                              3.4.2 Estimating growth rates for mature markets

                              Exhibit 06:  Global – Market size and forecast 2020 – 2025 ($ million)

                              Exhibit 07:  Global market: Year-over-year growth 2020 – 2025 (%)

4. Five Forces Analysis                         

               4.1 Five Forces Summary         

                              Exhibit 08:  Five forces analysis 2020 & 2025

               4.2 Bargaining power of buyers            

                              Exhibit 09:  Bargaining power of buyers

               4.3 Bargaining power of suppliers        

                              Exhibit 10: Bargaining power of suppliers

               4.4 Threat of new entrants     

                              Exhibit 11:  Threat of new entrants

               4.5 Threat of substitutes          

                              Exhibit 12: Threat of substitutes

               4.6 Threat of rivalry   

                              Exhibit 13: Threat of rivalry

               4.7 Market condition 

                              Exhibit 14:  Market condition – Five forces 2020

5. Market Segmentation by Type                    

               5.1 Market segments

                              The segments covered in this chapter are:

  • Biologics
  • Small molecules

                              Exhibit 15:  Type – Market share 2020-2025 (%)

               5.2 Comparison by Type          

                              Exhibit 16:  Comparison by Type

               5.3 Biologics – Market size and forecast 2020-2025      

                              Exhibit 17:  Biologics – Market size and forecast 2020-2025 ($ million)

                              Exhibit 18:  Biologics – Year-over-year growth 2020-2025 (%)

               5.4 Small molecules – Market size and forecast 2020-2025        

                              Exhibit 19:  Small molecules – Market size and forecast 2020-2025 ($ million)

                              Exhibit 20:  Small molecules – Year-over-year growth 2020-2025 (%)

               5.5 Market opportunity by Type          

                              Exhibit 21:  Market opportunity by Type

6. Customer landscape                        

                              Technavio’s customer landscape matrix comparing Drivers or price sensitivity, Adoption lifecycle, importance in customer price basket, Adoption rate and Key purchase criteria

                              Exhibit 22:  Customer landscape

7. Geographic Landscape                    

               7.1 Geographic segmentation

                              The regions covered in the report are:

  • North America
  • Europe
  • Asia
  • ROW

                              Exhibit 23:  Market share by geography 2020-2025 (%)

               7.2 Geographic comparison    

                              Exhibit 24:  Geographic comparison

               7.3 North America – Market size and forecast 2020-2025          

                              Exhibit 25:  North America – Market size and forecast 2020-2025 ($ million)

                              Exhibit 26:  North America – Year-over-year growth 2020-2025 (%)

               7.4 Europe – Market size and forecast 2020-2025         

                              Exhibit 27:  Europe – Market size and forecast 2020-2025 ($ million)

                              Exhibit 28:  Europe – Year-over-year growth 2020-2025 (%)

               7.5 Asia – Market size and forecast 2020-2025

                              Exhibit 29:  Asia – Market size and forecast 2020-2025 ($ million)

                              Exhibit 30:  Asia – Year-over-year growth 2020-2025 (%)

               7.6 ROW – Market size and forecast 2020-2025             

                              Exhibit 31:  ROW – Market size and forecast 2020-2025 ($ million)

                              Exhibit 32:  ROW – Year-over-year growth 2020-2025 (%)

               7.7 Key leading countries        

                              Exhibit 33:  Key leading countries

               7.8 Market opportunity by geography

                              Exhibit 34:  Market opportunity by geography ($ million)

8. Drivers, Challenges, and Trends                  

               8.1 Market drivers      

                              8.1.1 Novel approvals

                              8.1.2 Newborn screening tests

                              8.1.3 Huge unmet need for neuromuscular diseases therapeutics

               8.2 Market challenges              

                              8.2.1 Economic burden on patients

                              8.2.3 Fast progressive nature of neuromuscular diseases

                              8.2.3 Expiry of patents on major therapeutics

                              Exhibit 35:  Impact of drivers and challenges

               8.3 Market trends      

                              8.3.1 Technological advances

                              8.3.2 Inherited nature of neuromuscular diseases

                              8.3.3 Increasing research funding

9. Vendor Landscape                            

               9.1 Vendor landscape

                              Exhibit 36:  Vendor landscape

               9.2 Landscape disruption         

                              Exhibit 37:  Landscape disruption

                              Exhibit 38:  Industry risks

               9.3 Competitive Scenario        

10. Vendor Analysis               

               10.1 Vendors covered              

                              Exhibit 39:  Vendors covered

               10.2 Market positioning of vendors    

                              Exhibit 40: Market positioning of vendors

               10.3 AFM-Telethon    

                              Exhibit 41:  AFM-Telethon – Overview

                              Exhibit 42:  AFM-Telethon – Product and service

                              Exhibit 43:  AFM-Telethon – Key offerings

               10.4 Biogen Inc.          

                              Exhibit 44:  Biogen Inc. – Overview

                              Exhibit 45:  Biogen Inc. – Business segments

                              Exhibit 46:  Biogen Inc. – Key offerings

                              Exhibit 47:  Biogen Inc. – Segment focus

               10.5 Brainstorm Cell Therapeutics Inc.              

                              Exhibit 48:  Brainstorm Cell Therapeutics Inc. – Overview

                              Exhibit 49:  Brainstorm Cell Therapeutics Inc. – Product and service

                              Exhibit 50:  Brainstorm Cell Therapeutics Inc. – Key news

                              Exhibit 51:  Brainstorm Cell Therapeutics Inc. – Key offerings

               10.6 F. Hoffmann-La Roche Ltd.

               Exhibit 52:  F. Hoffmann-La Roche Ltd. – Overview        

               Exhibit 53:  F. Hoffmann-La Roche Ltd. – Business segments     

               Exhibit 54:  F. Hoffmann-La Roche Ltd. – Key offerings 

               Exhibit 55:  F. Hoffmann-La Roche Ltd. – Segment focus             

               10.7 Mitsubishi Chemical Holdings Corp.         

                              Exhibit 56:  Mitsubishi Chemical Holdings Corp. – Overview

                              Exhibit 57:  Mitsubishi Chemical Holdings Corp. – Business segments

                              Exhibit 58:  Mitsubishi Chemical Holdings Corp. – Key offerings

                              Exhibit 59:  Mitsubishi Chemical Holdings Corp. – Segment focus

               10.8 Novartis AG        

                              Exhibit 60:  Novartis AG – Overview

                              Exhibit 61:  Novartis AG – Business segments

                              Exhibit 62:  Novartis AG – Key offerings

                              Exhibit 63:  Novartis AG – Segment focus

               10.9 Pfizer Inc.            

                              Exhibit 64:  Pfizer Inc. – Overview

                              Exhibit 65:  Pfizer Inc. – Business segments

                              Exhibit 66:  Pfizer Inc. – Key offerings

                              Exhibit 67:  Pfizer Inc. – Segment focus

               10.10 PTC Therapeutics Inc.   

                              Exhibit 68:  PTC Therapeutics Inc. – Overview

                              Exhibit 69:  PTC Therapeutics Inc. – Business segments

                              Exhibit 70:  PTC Therapeutics Inc. – Key offerings

                              Exhibit 71:  PTC Therapeutics Inc. – Segment focus

               10.11 Sanofi SA           

                              Exhibit 72:  Sanofi SA – Overview

                              Exhibit 73:  Sanofi SA – Business segments

                              Exhibit 74:  Sanofi SA – Key offerings

                              Exhibit 75:  Sanofi SA – Segment focus

               10.12 Sarepta Therapeutics Inc.           

                              Exhibit 76:  Sarepta Therapeutics Inc. – Overview

                              Exhibit 77:  Sarepta Therapeutics Inc. – Business segments

                              Exhibit 78:  Sarepta Therapeutics Inc. – Key offerings

                              Exhibit 79:  Sarepta Therapeutics Inc. – Segment focus

11. Appendix                           

               11.1 Scope of the report         

                              11.1.1 Market definition

                              11.1.2 Objectives

                              11.1.3 Notes and caveats

               11.2 Currency conversion rates for US$            

                              Exhibit 80:  Currency conversion rates for US$

               11.3 Research Methodology   

                              Exhibit 81:  Research Methodology

                              Exhibit 82:  Validation techniques employed for market sizing

                              Exhibit 83:  Information sources

               11.4 List of abbreviations        

                              Exhibit 84:  List of abbreviations

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio